Phosphodiesterase 5 inhibition in essential hypertension - PubMed (original) (raw)
Review
Phosphodiesterase 5 inhibition in essential hypertension
Lorenzo Ghiadoni et al. Curr Hypertens Rep. 2008 Feb.
Abstract
Phosphodiesterase (PDE) 5 inhibitors reduce cyclic guanylate monophosphate breakdown, promoting vascular relaxation in the corpora cavernosa and penile erection during sexual stimulation. Sildenafil, vardenafil, and tadalafil were approved as effective treatments for male erectile dysfunction. Because PDE5 is present in artery and vein smooth muscle cells throughout the body, PDE5 inhibitors have mild systemic vasodilatory effects and thus the potential to impact the vascular system. The US Food and Drug Administration has approved PDE5 inhibitors for treating pulmonary hypertension. Moreover, their systemic vasodilating properties theoretically make these drugs suitable for treating hypertension. Studies indicate that PDE5 inhibition may be an option for reducing blood pressure in hypertensive patients. Additional benefits may be related to improved arterial stiffness and endothelial dysfunction, two early vascular abnormalities characterizing essential hypertension. More investigation is needed on PDE5 inhibitors as antihypertensive drugs, especially with slow-release formulations or compounds with long half-life. Studies on safety during long-term administration, interactions with antihypertensive and nonantihypertensive drugs, and effect on target organ damage are needed.
Similar articles
- Phosphodiesterase-5 inhibitors and their hemodynamic effects.
Prisant LM. Prisant LM. Curr Hypertens Rep. 2006 Aug;8(4):345-51. doi: 10.1007/s11906-006-0075-y. Curr Hypertens Rep. 2006. PMID: 16884667 Review. - Effect of the phosphodiesterase 5 inhibitors sildenafil, tadalafil and vardenafil on rat anococcygeus muscle: functional and biochemical aspects.
Toque HA, Priviero FB, Zemse SM, Antunes E, Teixeira CE, Webb RC. Toque HA, et al. Clin Exp Pharmacol Physiol. 2009 Apr;36(4):358-66. doi: 10.1111/j.1440-1681.2008.05071.x. Epub 2008 Oct 15. Clin Exp Pharmacol Physiol. 2009. PMID: 18986324 Free PMC article. - Failure of PDE5 inhibitor use: a case of nonresponder? (CME).
Chung E. Chung E. J Sex Med. 2010 Apr;7(4 Pt 1):1321-3. doi: 10.1111/j.1743-6109.2010.01772.x. J Sex Med. 2010. PMID: 20492423 No abstract available. - Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease.
Ravipati G, McClung JA, Aronow WS, Peterson SJ, Frishman WH. Ravipati G, et al. Cardiol Rev. 2007 Mar-Apr;15(2):76-86. doi: 10.1097/01.crd.0000233904.77128.49. Cardiol Rev. 2007. PMID: 17303994 Review. - The ENDOTRIAL study: a spontaneous, open-label, randomized, multicenter, crossover study on the efficacy of sildenafil, tadalafil, and vardenafil in the treatment of erectile dysfunction.
Jannini EA, Isidori AM, Gravina GL, Aversa A, Balercia G, Bocchio M, Boscaro M, Carani C, Corona G, Fabbri A, Foresta C, Forti G, Francavilla S, Granata AR, Maggi M, Mansani R, Palego P, Spera G, Vetri M, Lenzi A; Endotrial Study Group. Jannini EA, et al. J Sex Med. 2009 Sep;6(9):2547-60. doi: 10.1111/j.1743-6109.2009.01375.x. Epub 2009 Jun 29. J Sex Med. 2009. PMID: 19570039 Clinical Trial.
Cited by
- Effect of Torilis japonica Fruit Extract for Endothelium-Independent Vasorelaxation and Blood Pressure Lowering in Rats.
Park J, Shin S, Kim Y, Bu Y, Choi HY, Lee K. Park J, et al. Int J Mol Sci. 2024 Jul 25;25(15):8101. doi: 10.3390/ijms25158101. Int J Mol Sci. 2024. PMID: 39125672 Free PMC article. - Sildenafil-evoked photoreceptor oxidative stress in vivo is unrelated to impaired visual performance in mice.
Berkowitz BA, Podolsky RH, Lins Childers K, Saadane A, Kern TS, Roberts R, Olds H, Joy J, Richards C, Rosales T, Schneider M, Schilling B, Orchanian A, Graffice E, Sinan K, Qian H, Harp L. Berkowitz BA, et al. PLoS One. 2021 Mar 4;16(3):e0245161. doi: 10.1371/journal.pone.0245161. eCollection 2021. PLoS One. 2021. PMID: 33661941 Free PMC article. - RhoBTB1 protects against hypertension and arterial stiffness by restraining phosphodiesterase 5 activity.
Mukohda M, Fang S, Wu J, Agbor LN, Nair AR, Ibeawuchi SC, Hu C, Liu X, Lu KT, Guo DF, Davis DR, Keen HL, Quelle FW, Sigmund CD. Mukohda M, et al. J Clin Invest. 2019 Mar 21;129(6):2318-2332. doi: 10.1172/JCI123462. J Clin Invest. 2019. PMID: 30896450 Free PMC article. - Optimization of Extraction Technology of Majun Mupakhi Ela and its Effect on Hydrocortisone-induced Kidney Yang Deficiency in Mice.
Reheman A, Gao ZY, Tursun X, Pu XP, Wu T, He F, Zhao X, Aisa HA. Reheman A, et al. Sci Rep. 2019 Mar 15;9(1):4628. doi: 10.1038/s41598-019-41006-6. Sci Rep. 2019. PMID: 30874604 Free PMC article. - Phosphodiesterase type 5 inhibitors and kidney disease.
Afsar B, Ortiz A, Covic A, Gaipov A, Esen T, Goldsmith D, Kanbay M. Afsar B, et al. Int Urol Nephrol. 2015 Sep;47(9):1521-8. doi: 10.1007/s11255-015-1071-4. Epub 2015 Aug 5. Int Urol Nephrol. 2015. PMID: 26242375 Review.
References
- J Am Coll Cardiol. 2002 Oct 2;40(7):1232-40 - PubMed
- J Cell Sci. 2000 May;113 ( Pt 10):1671-6 - PubMed
- Proc Soc Exp Biol Med. 1996 Jan;211(1):1-6 - PubMed
- Drugs. 2002;62(2):265-84 - PubMed
- J Androl. 2002 Nov-Dec;23(6):763-71 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical